Press Release

Printer Friendly Version View printer-friendly version
<< Back
Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States

SAN FRANCISCO, July 9, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats is commercially available to veterinarians in the United States.

Kindred Biosciences, Inc. Logo

Mirataz is the first and only transdermal medication for the management of weight loss in cats approved by the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine. Unintended weight loss in cats is a serious and potentially fatal condition that represents the leading cause of visits to the veterinarian for cats. Mirataz is a serotonin (5HT2A, 5HT2C, and 5HT3) and histamine (H1) receptor antagonist, which has demonstrated body weight gain in cats experiencing weight loss. The product is classified as a weight gain drug and can be used in cats experiencing unintended weight loss caused by varying underlying conditions. Formulated with KindredBio's proprietary Accusorb™ technology, Mirataz is applied topically to the cat's inner ear (pinna) once a day, providing an attractive application route instead of oral dosing.

"With approximately nine million cats experiencing unintended weight loss due to underlying conditions each year, we are very pleased to offer this first-in-class therapy to veterinarians," stated Denise Bevers, Co-Founder and Chief Operating Officer of KindredBio. "As our first approved product, Mirataz confirms our strategy of quickly and cost-efficiently developing animal health therapeutics. Furthermore, the speed with which our team brought this product to market following FDA-approval illustrates the caliber of talent within our commercial, operations, and supply-chain teams."

To order Mirataz, veterinarians may contact their preferred animal health distributor, call 1-888-608-2542, or visit http://kindredbio.com.

Important Safety Information

Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs).  Not for human use.  Keep out of reach of children.  Wear gloves to apply and wash hands after.  Avoid contact with treated cat for 2 hours following application.  The most common adverse reactions include application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting.  Please see the full Prescribing Information.

About Kindred Biosciences
Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. KindredBio's first approved drug is Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Contacts
For investor inquiries:
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438

For media inquiries:
Jeanene Timberlake
jtimberlake@rooneyco.com
(646) 770-8858

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-announces-commercial-availability-of-mirataz-mirtazapine-transdermal-ointment-to-veterinarians-in-the-united-states-300677202.html

SOURCE Kindred Biosciences, Inc.